Allogeneic hematopoietic stem cell transplantation for non-Hodgkin’s lymphoma in Queen Mary Hospital—a single centre experience  by Lie, A.K.W. et al.
2-9). Acute GvHD (grade I, at day 47 and day 97 [patient who
had prior allogeneic transplant with chronic GvHD]) was observed
in 2 patients while mild chronic GvHD in 7 (grade II, one due to
donor lymphocyte infusion). With a median follow-up of 13.5
months (9.5-20), 12 patients were alive and 9 remained in CR. No
transplant related mortality was seen but 2 AML patients had early
relapsed (day 59, and 130). Conclusion: The NMT regimen
with triple GVHD prophylaxis appears to be safe with no trans-
plant related mortality. It may be an effective treatment for hema-
tological malignancies in Asian patients with high risk features.
Longer follow-up and additional patients are required to conﬁrm
the efﬁcacy.
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SEQUENTIAL ADMINISTRATION OF SARGRAMOSTIM (GM-CSF) AND
FILGRASTIM (G-CSF) IN PEDIATRIC ALLOGENEIC STEM CELL TRANS-
PLANT (AlloSCT) RECIPIENTS UNDERGOING MYELOABLATIVE (MA)
CONDITIONING: COST-EFFECTIVE AND MORE RAPID PLATELET RE-
COVERY IN UCB RECIPIENTS
Militano, O.1, Boskoff, B.2, Del Toro, G.3, van deVen, C.3,
Satwani, P.3, Bradley, B.3, George, D.3, Garvin, J.H.3, Bhatia, M.3,
Roman, E.3, Wolownik, K.3, Foley, S.3, Hawks, R.3, Shwartz, J.4,
Cheung, K.5, Cairo, M.S.3,4,6 1. Department of Pharmacy, New York
Presbyterian Hospital, New York, NY; 2. Vanderbilt University, Nash-
ville, TN; 3. Department of Pediatrics, Columbia University, New York,
NY; 4. Department of Pathology, Columbia University, New York, NY;
5. Department of Biostatistics, Columbia University, New York, NY; 6.
Department of Medicine, Columbia University, New York, NY.
G-CSF or GM-CSF can hasten myeloid engraftment post MA
AlloSCT. GM-CSF is an earlier and broader acting CSF, which
also induces more TH1. DC1 immune subsets preferentially
compared to G-CSF. The objective of this study is to evaluate
efﬁcacy/safety of sequential administration of GM-CSF fol-
lowed by G-CSF in children s/p MA AlloSCT. From 1/01-6/05
we enrolled 34 children: mean age 7.2 yrs; wt 32.3 kg; M:F 
19:15; poor:average risk  13:21, TBI vs non-TBI based con-
ditioning  12:22; MFD vs umbilical cord blood (UCB) 
12:22. Indications for AlloSCT included malignant (MDS,
ALL, AML, APL, NHL [n  22]) and non-malignant (SAA,
HLH, SCD, B-thal [n  12]) disorders. GM-CSF (250 g/m2
IV QD) was initiated on day 0 post stem cell infusion. GM-CSF
was switched to G-CSF (10 g/kg IV QD) when WBC 300/
mm3  2 days. G-CSF was continued until ANC 2500/mm3 
2 days, then tapered to maintain ANC 1000/mm3. GVHD
prophylaxis: tacrolimus (target 5-20 ng/mL) and mycophenolate
as previously described (Osunkwo/Cairo, BBMT 2004). All pts
were prophylaxed against PCP, HSV, CMV, and fungal infec-
tions. There were no statistically signiﬁcant differences in base-
line characteristics between MFD vs UCB groups. Mean
CD34 cell dose/kg  36.3  105 and TNC dose/kg  39.3 
107. Median time to WBC 300/mm3  15.5 d (10 vs 19.5 d
MFD vs UCB). Median time of switch from GM-CSF (WBC
300/mm3) to G-CSF and myeloid engraftment (ANC 500/
mm3  2 d) was 0.5 d (1.5 vs 3.5 d MFD vs UCB). Median time
to myeloid and platelet engraftment (untransfused count
20000/mm3  7 d) were 17 d (13 vs 23.5 d MFD vs UCB) and
28 d (19 vs 33.5 d MFD vs UCB). Kaplan-Meier probability of
1 year OS was 67.2% (CI: 50.3-84.1). Adverse events attribut-
able to G-CSF (n  1) or GM-CSF (n  3) were: bone pain,
pleural and pericardial effusions. Of these, 3/4 pts received
concomitant oprelvekin (IL-11). Infections occurring prior to
day 60 included 21 (62%) pts with CVL bacteremia (coagulase
() staphylococci [n  9], gram () bacilli [n  10]) and 2 (6%)
pts with invasive fungal infections. This pilot study demon-
strated safety and efﬁcacy of sequential GM-CSF/G-CSF ad-
ministration in pediatric AlloSCT recipients. Myeloid recovery
after WBC 300/mm3 on GM-CSF only took 1-3 days after
switch to G-CSF. Platelet engraftment following UCBT ap-
pears more rapid with sequential GM-CSF/G-CSF compared to
historical controls. Sequential GM-CSF/G-CSF may be more
cost-effective than G-CSF alone (cost-saving of $1402/patient
based on 2004 Red Book AWP).
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ALLOGENEIC STEM CELL TRANSPLANTATION (SCT) FOR THE TREAT-
MENT OF 15 PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLO-
BINURIA (PNH) IN BRAZIL
Oliveira, M.M., Bonﬁm, C., Bitencourt, M., Funke, V., Setubal, D.,
Ruiz, J., Medeiros, C.R., Zanis-Neto, J., Pasquini, R. Federal Univer-
sity of Parana, Curitiba, PR, Brazil.
PNH is a clonal disorder caused by acquired mutations of the
PIG-A gene. Many pts achieve long term survival if adverse
factors are not present. SCT can be curative for young pts with
severe pancytopenia, massive hemolysis, thrombotic complica-
tions or leukemic transformation. SCT complications are fre-
quent reported due to an increased risk of graft failure and
transplant related mortality. In this study we retrospectively
analyze 15 pts with PNH submitted to SCT in our BMT center.
Period: 03/88-02/05. Indication for SCT: severe pancytopenia:
12 pts, thrombosis: 2 pts and hemolysis: 1 pt. Age: 14-42 y (M:
29 y). Gender: 6F/9M. Time from diagnosis to SCT ranged
from 2 to 133 months (M: 29.5 mo). Previous blood transfu-
sions: 25 UI (range: 8-200 UI). Total nucleated cell infused:
1.72-4.56  108/kg (median: 2.7). Donor type: HLA identical
siblings: 14 pts, unrelated identical donor: 1 pt. Stem cell
source: bone marrow: 14 pts; peripheral blood: 1 pt. Preparatory
regimen: busulfan (BU) 12 mg/kg  cyclophosphamide (CY)
120 mg/kg: 11 pts (1 pt received BU 16 mg/kg), BU 8 mg/kg 
ﬂudarabine 125 mg/m2: 2 pts; CY 120 mg/kg  TBI ATG: 1
pt and CY 200 mg/kg: 1 pt. GVHD prophylaxis: methotrexate 
cyclosporine: 12 pts; others: 3 pts. Eleven pts are alive without
evidence of PNH with a median follow-up of 1691 days (range:
125-5998 days). Estimated 5 year survival: 73%. Two pts died
before day 28 and were not evaluable for engraftment. 13 pts
engrafted and the median time to reach ANC 	500/l was 19
days (range: 14-25). Mucositis grade III-IV occurred in 7 pts.
Two patients developed grade III-IV acute GVHD. One pt had
progressive extensive chronic GVHD and another one had de
novo extensive C-GVHD. No pt developed veno-occlusive dis-
ease. Four pts (median age of 36.5 yr) died on day 10, 11,
71 and 330 after SCT. Causes of death included infection (2
pts) and GVHD (2 pts).We conclude that pts with PNH and life
threatening complications can achieve long term survival after
SCT when HLA identical donors are used. In this group of
patents we did not observe signiﬁcant transplant related com-
plications.
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ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR
NON-HODGKIN’S LYMPHOMA IN QUEEN MARY HOSPITAL—A SINGLE
CENTRE EXPERIENCE
Lie, A.K.W., Leung, A.Y.H., Liang, R. Division of Hematology and
Bone Marrow Transplantation, The University of Hong Kong, Hong
Kong.
Objectives: Non-Hodgkin’s lymphoma (NHL) is one of the
major indications for haematopoietic stem cell transplantation
(HSCT). For chemo-sensitive relapsed cases, autologous HSCT is
often the treatment of choice. Relapsed cases after autologous
HSCT as well as those with extensive disease generally have poor
prognosis and allogeneic HSCT becomes the only option for a
cure. We summarized our experience in Queen Mary Hospital
regarding the outcome of allogeneic HSCT for this disease.Meth-
ods: Hospital records of allogeneic HSCT for underlying NHL in
the past fourteen years were retrieved. Clinical data were summa-
rized according to the pre-HSCT characteristics, disease relapse
and transplant-related mortality. Event-free (deﬁned as either dis-
ease relapse or death after HSCT) and overall survival were eval-
uated by Kaplan-Meier analysis. Results: Since 1991, a total of 48
NHL patients (M:F 25:23) have undergone allogeneic HSCT. The
median age was 42 (range: 23-63 years). Histological diagnoses
were obtained from 40 patients and they comprised both B-cell
(Burkitt or Burkitt-like  5, diffuse large B-cells  19, follicular 
3, maltoma  1, Mantle cell  3) or T-cell lymphoma (angioim-
munoblastic T-cell  3, T-lymphoblastic  4, peripheral T-cell 
2). Allogeneic HSCT was performed mostly as salvage therapy for
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chemosensitive relapses after chemotherapy and autologous
HSCT. Source of HSCT included HLA-matched siblings (n 
41), matched unrelated donors (n  6) and parents (n  1).
Forty-ﬁve patients received myeloablative and 3 received reduced
intensity conditioning. The median EFS and OS were 38 and 40
months and at 160 months, the EFS and OS were 47% and 50%.
When patients with diffuse large B-cell lymphoma were separately
analyzed, the EFS and OS at 40 months were about 52% and none
of the patients had disease relapse or mortality thereafter. Con-
clusion: We demonstrated that allogeneic HSCT may offer a cure
for high risk NHL patients. Our results compared favorably with
those reported in the literature.
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RECIPIENT OUTCOMES DATA COLLECTION AND REPORTING FOR
CORD BLOOD BANK FOLLOW-UP AND QUALITY ASSURANCE PUR-
POSES: THE NATIONAL MARROW DONOR PROGRAM EXPERIENCE
Halet, M.1, Confer, D.1, Welte, K.1, Matlack, M.1, King, R.1, Boo, M.1,
Kurtzberg, J.2 1. National Marrow Donor Program, Minneapolis, MN;
2. Duke University Medical Center, Durham, NC.
Cord blood banks (CBB) are required to monitor clinical out-
comes of cord blood unit (CBU) transplants performed by trans-
plant centers (TC). Obtaining accurate and timely follow-up data
on clinical outcomes from the TC can be very difﬁcult. The
National Marrow Donor Program (NMDP), by virtue of their
comprehensive activities with member network centers, collects
outcomes data on recipients transplanted with either cord blood or
adult donor cells. NMDP member transplant centers are required
to submit data at deﬁned intervals as part of their participation
agreement. A system is in place to monitor compliance that in-
cludes a due process procedure for non-compliant centers. Recip-
ients sign an IRB-approved consent form for data submission to
the NMDP. All submitted data are veriﬁed through system checks
at time of data entry. Identiﬁed errors are subject to a formal error
correction process. Transplant centers are audited on a four year
cycle to assure the accuracy and integrity of the data provided. At
any given time,	90% of NMDP centers are compliant with forms
submission requirements. The data elements include information
on the results of the thaw, infusion related reactions, preparative
regimens, neutrophil and platelet engraftment, GVHD, relapse,
survival and death. Member cord blood banks receive a quarterly
report from the NMDP which includes comprehensive data on the
individual recipients for which their CBUs were used. The data
include recipient demographics, infused cell dose, degree of HLA
match, engraftment, GVHD, relapse, survival, and cause of death.
While outcomes data are reported quarterly to member banks,
thaw data are reported and reviewed on a continuous basis. TNC
recoveries that are low (60%) or high (	100%) are reviewed by
NMDP staff to detect problems with CBU potency that might be
linked to a certain bank, shipping procedure or thawing protocol at
a TC. Future directions include trending analysis reports and
review with the NMDP Quality Standards subcommittee. The
NMDP’s process for reporting quality assurance data to member
banks is a valuable service that is unlikely to be feasible in a single
bank.
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ISOPHOSPHORAMIDE MUSTARD-LYSINE (IPM-L; ZIO-201): A NEW AL-
KYLATOR FOR BONE MARROW TRANSPLANTS
Morgan, L.1, Struck, R.2, Rodgers, A.3, Jursic, B.4, Waud, W.3,
Papagiannis, C.5, Gale, R.P.6 1. DEKK-TEC, Inc., New Orleans, LA;
2. Cancer Medica, LLC, Birmingham, AL; 3. Southern Research Insti-
tute, Birmingham, AL; 4. Chemistry Department, University of New
Orleans, LA; 5. MPI Research, Mattawan, MI; 6. ZIOPHARM On-
cology, Charlestown, MA.
Alkylators are widely used in conditioning regimens for bone
marrow transplants. IPM is a bi-functional alkylator with cross-
linking through G:C base sequences resulting in irreparable inter-
strand DNA cross-linking producing cell death. IPM alkylates
DNA as a phosphorodiamidate and may cross-link DNA differ-
ently from phosphoramide mustard (PM) the major DNA-cross-
linking moiety of cyclophosphamide (CPA). IPM is active in di-
verse cancer models but its chemical instability precluded
pharmaceutical development; CPA and ifosfamide (IFOS) were
developed as alternatives. We stabilized IPM with lysine (IPM-L;
ZIO-201) and tested it in preclinical sub-acute pharmacology and
toxicology models and in mice with human cancer xenografts.
ZIO-201 and IPM were given IV daily  3 d. ZIO-201 sub-acute
LD10/50 in adult mice was 133 and 220 mg/kg (combined sexes)
compared to 119 and 149 mg/kg for IPM. Bone marrow failure was
the dose-limiting toxicity (DLT) of both drugs. In the MX-1
human breast cancer model, ZIO-201 was better than IPM: MTD:
93 vs. 40 mg/kg/dose and tumor versus control life extension
(T-C): 10.2 versus 2.1 d. Because ZIO-201 (unlike cyclophospha-
mide [CPA] and ifosfamide [IFOS]) is not metabolized to acrolein
or acetaldehydes, there was no kidney, bladder or CNS toxicity.
ZIO-201 is in phase-1 trials in humans: data will be presented.
Using ZIO-201 may increase the safety and efﬁcacy of this class of
alkylators in clinical settings where high-dose CPA and IFOS are
used, like bone marrow transplants. Possible dose increases and
activity in CPA- and IFOS-resistant cancers may broaden the
target range. Supported by grant R44 CA83552 from the NCI/
SBIR program.
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ADOPTIVE IMMUNOTHERAPY WITH TUMOR-DERIVED DONOR LYM-
PHOCYTES AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANS-
PLANTATION
Hardy, N.M.1, Fellowes, V.1, Mariotti, J.1, Carter, C.2, June, C.3,
Levine, B.3, Hakim, F.1, Vonderheide, R.3, Gress, R.1, Read, E.J.2,
Fowler, D.1, Bishop, M.R.1 1. National Cancer Institute, National
Institutes of Health (NIH), Bethesda, MD; 2. Clinical Center, NIH,
Bethesda, MD; 3. University of Pennsylvania, Philadelphia, PA.
Treatment of refractory or recurrent malignancy with donor
lymphocyte infusion (DLI) after allogeneic hematopoietic stem cell
transplantation (alloHSCT) is limited in efﬁcacy, and graft-vs-
tumor (GVT) is often accompanied by graft-versus-host disease
(GVHD). After alloHSCT, lymphocytes inﬁltrating residual tu-
mor are likely of donor origin. Compared with DLI, they may
provide enhanced antigen speciﬁcity and maintain tumor-speciﬁc
homing, thus generate better GVT with less GVHD. We are
testing this hypothesis through administration of ex-vivo activated
tumor-derived lymphocytes (TDL) after alloHSCT. Clinical eval-
uation of TDL therapy was initiated with a 51 year-old woman for
metastatic breast cancer whose disease progressed after matched-
sibling alloHSCT and subsequent conventional therapy plus DLI.
Metastases were surgically removed two weeks after administration
of unmanipulated DLI. Lymphocytes were liberated from 9.4 cm
of tumor and expanded for 14 days with anti-CD3/CD28-coated
magnetic beads (3:1 bead-to-total nucleated cell ratio) and media
containing IL-2 (100 or 1000 IU/mL). The cell products from the
two culture conditions were similar. The process yielded 42.5 
106 cells, 33% expressing CD3, and generated 14.7  109 TDL,
85% expressing CD3 (a 3.1-log T cell expansion). There was no
tumor contamination of the T cell product by immunohistochem-
istry. Chimerism analysis revealed the TDL to be of donor origin.
Flow cytometry showed an increase in the CD4/CD8 ratio from
1.3 to 1.9 after expansion. 76% of CD8 and 31% of CD4 cells
secrete IFN-, and none secretes IL-2, IL-4 or IL-10. 76% of
CD8 and 57% of CD4 cells expressed CXCR3. Three infusions of
TDL were given in a dose-escalating manner (5, 25 and 100  106
CD3 cells/kg). Two additional infusions were given in conjunc-
tion with low-dose IL-2, the second of which was preceded by one
cycle of paclitaxel and trastuzumab cytoreductive therapy. No
infusion-related or delayed toxicities were observed. The patient
had no evidence of GVHD, even after the highest dose of 108
allogeneic T cells. Evaluation of the remaining thoracic lesion
demonstrated progressive disease after the ﬁrst two TDL infu-
sions, transient disease stability after the third and fourth infusions,
and at present, the patient has stable disease one month after the
ﬁfth infusion. This is the ﬁrst clinical report of the application of
TDL and represents a novel approach for adoptive immunother-
apy in the setting of alloHSCT.
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